tirzepatide cardiovascular outcomes trial results august 2025 event risk assessment: a pre-specified meta-analysis Can Dual Incretin Receptor Agonists

The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, narrowing but not eliminating legitimate compounding activity

Results come on a case to case basis, because each of us has a different body reaction

These agents are FDA-approved primarily for the management of type 2 diabetes mellitus and, for specific products (Wegovy, Saxenda, Zepbound), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

Being overweight or obese increases the risk of several severe health conditions, including heart disease, stroke, diabetes, and certain types of cancer

PlexusDx accepts HSA/FSA funds and requires no insurance, membership fee, or hidden charges